| pubmed-article:20054549 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20054549 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20054549 | lifeskim:mentions | umls-concept:C0278689 | lld:lifeskim |
| pubmed-article:20054549 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:20054549 | lifeskim:mentions | umls-concept:C0210657 | lld:lifeskim |
| pubmed-article:20054549 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:20054549 | pubmed:dateCreated | 2010-8-13 | lld:pubmed |
| pubmed-article:20054549 | pubmed:abstractText | Carboplatin-based combinations are established in platinum-sensitive recurrent ovarian cancer. To improve the therapeutic index, new platinum-based combinations are required. Pemetrexed is a multi-targeted antifolate inhibiting thymidylate synthase. The aim of this study was to determine the maximally tolerated dose (MTD) and dose-limiting toxicity (DLT) and to characterize toxicities of the combination of pemetrexed (Pem) and carboplatin (Cb). | lld:pubmed |
| pubmed-article:20054549 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20054549 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20054549 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20054549 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20054549 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20054549 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20054549 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20054549 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20054549 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:20054549 | pubmed:issn | 1432-0843 | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:BauknechtThom... | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:MahnerSvenS | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:SehouliJalidJ | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:LichteneggerW... | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:LookKatherine... | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:JaenickeFritz... | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:CamaraOumarO | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:Oskay-Oezceli... | lld:pubmed |
| pubmed-article:20054549 | pubmed:author | pubmed-author:RunnebaumIngo... | lld:pubmed |
| pubmed-article:20054549 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20054549 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:20054549 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20054549 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20054549 | pubmed:pagination | 861-8 | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:meshHeading | pubmed-meshheading:20054549... | lld:pubmed |
| pubmed-article:20054549 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20054549 | pubmed:articleTitle | A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. | lld:pubmed |
| pubmed-article:20054549 | pubmed:affiliation | Department of Obstetrics and Gynecology, Charité University Hospital, Berlin, Germany. sehouli@aol.com | lld:pubmed |
| pubmed-article:20054549 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20054549 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20054549 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20054549 | lld:pubmed |
